CBX3

Across TCGA pan-cancer cohorts, CBX3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CBX3 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CBX3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CBX3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where CBX3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.474	0.857	<.001	79	view →
LSCC	OS	Tertile	All	0.964	0.762	.016	14	view →
LUAD	OS	Median	III,IV	1.000	0.661	.004	12	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
CCRCC	DFS	Tertile	IV	0.887	0.260	.024	6	view →
PDAC	DFS	Quartile	All	0.926	0.657	.020	5	view →
GBM	OS	Tertile	All	0.525	0.278	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CBX3–HNSC (DFS)

Open the HNSC breakdown →